Is Infinium Pharma overvalued or undervalued?

As of 16 September 2025, Infinium Pharma's valuation grade has moved from attractive to fair, indicating a shift in market perception. The company appears to be fairly valued based on its current financial metrics. Key ratios include a PE ratio of 46.55, an EV to EBITDA of 25.99, and a ROCE of 21.16%.
In comparison to its peers, Infinium Pharma's PE ratio is significantly higher than that of Cipla at 23.31 and Dr. Reddy's Labs at 19.25, both of which are considered attractive. This suggests that while Infinium Pharma is fairly valued, it may be overvalued relative to its more attractively priced peers. Additionally, the company's stock has underperformed the Sensex year-to-date, with a return of -15.64% compared to the Sensex's 6.74%, further supporting the notion that the stock may not be a compelling investment at its current price.